All In Biotech

Drug Trial Radar · NCT06925737

A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)

A Phase 3, Open-label Study of Ifinatamab Deruxtecan Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (IDeate-Prostate01)

Last checked: Nov 19, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 1,440 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

1,440

Planned (sponsor's estimate)

Start

May 13, 2025

Primary completion

Jun 26, 2028

Study completion Jan 6, 2031

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
Collaborators
Daiichi Sankyo
First posted
Apr 13, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Researchers are looking for new ways to treat metastatic castration-resistant prostate cancer (mCRPC). Researchers have designed a study medicine called ifinatamab deruxtecan (also called I-DXd or MK-2400) to treat mCRPC. The goal of this study is to learn if people who receive I-DXd live longer overall and live longer without the cancer growing or spreading than people who receive chemotherapy.

Conditions

  • Prostate Cancer
  • Prostatic Neoplasms

Interventions

  • Ifinatamab deruxtecanDrug

    Administered via intravenous (IV) infusion every 3 weeks (q3w) until disease progression, unacceptable adverse events (AEs), or other cessation of treatment

  • DocetaxelDrug

    Administered via IV infusion q3W until disease progression, unacceptable adverse events (AEs), or other cessation of treatment

  • PrednisoneDrug

    Oral tablet administered once per day or per approved product label

  • Rescue MedicationDrug

    Before administering each dose of I-DXd, premedication is required for prevention of nausea and vomiting with a 2 or 3 drug combination regimen (eg, corticosteroids with either a 5-HT3 receptor antagonist or an NK-1 receptor antagonist and other drugs as indicated) per approved product label

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Survival (OS)Time frame: Up to approximately 36 months
  2. Radiographic Progression Free Survival (rPFS)Time frame: Up to approximately 36 months

Locations

303 sites in 35 countries. Site status is shown where the registry gives one.

  • Mayo Clinic in Arizona - Phoenix ( Site 0044)

    Phoenix, Arizona · Recruiting

  • Community Cancer Institute ( Site 0081)

    Clovis, California · Recruiting

  • City of Hope Comprehensive Cancer Center ( Site 0049)

    Duarte, California · Recruiting

  • City of Hope Lennar Foundation Cancer Center ( Site 0059)

    Irvine, California · Recruiting

  • Moores Cancer Center ( Site 0010)

    La Jolla, California · Recruiting

  • Veterans Affairs Long Beach Healthcare System ( Site 0058)

    Long Beach, California · Recruiting

  • Cedars-Sinai Medical Center ( Site 0068)

    Los Angeles, California · Recruiting

  • UCLA Hematology/Oncology - Santa Monica ( Site 0002)

    Los Angeles, California · Recruiting

  • University of California, Irvine (UCI) Health - UC Irvine Medical Center ( Site 0006)

    Orange, California · Recruiting

  • Stanford Cancer Center ( Site 0046)

    Palo Alto, California · Recruiting

  • Rocky Mountain Regional Veterans Affairs Medical Center ( Site 0053)

    Aurora, Colorado · Recruiting

  • Yale-New Haven Hospital-Yale Cancer Center ( Site 0050)

    New Haven, Connecticut · Recruiting

  • Veterans Affairs Connecticut Healthcare System ( Site 0062)

    West Haven, Connecticut · Recruiting

  • The GW Medical Faculty Associates ( Site 0057)

    Washington D.C., District of Columbia · Completed

  • Washington DC Veterans Affairs Medical Center ( Site 0056)

    Washington D.C., District of Columbia · Recruiting

  • Clermont Oncology Center ( Site 0087)

    Clermont, Florida · Recruiting

  • Mayo Clinic in Florida-Mayo Clinic Comprehensive Cancer Center ( Site 0077)

    Jacksonville, Florida · Recruiting

  • Mid Florida Hematology and Oncology Center ( Site 0086)

    Orange City, Florida · Recruiting

  • Emory University School of Medicine- Grady Campus ( Site 0103)

    Atlanta, Georgia · Recruiting

  • Winship Cancer Institute, Emory University ( Site 0003)

    Atlanta, Georgia · Recruiting

  • Rush University Medical Center-Hematology and Oncology ( Site 0028)

    Chicago, Illinois · Recruiting

  • University of Illinois at Chicago-University of Illinois Cancer Center ( Site 0063)

    Chicago, Illinois · Recruiting

  • University of Kentucky Chandler Medical Center ( Site 0048)

    Lexington, Kentucky · Recruiting

  • Greenebaum Comprehensive Cancer Center ( Site 0021)

    Baltimore, Maryland · Recruiting

  • Beth Israel Deaconess Medical Center ( Site 0043)

    Boston, Massachusetts · Recruiting

  • Dana Farber Cancer Institute ( Site 0012)

    Boston, Massachusetts · Recruiting

  • University of Michigan ( Site 0005)

    Ann Arbor, Michigan · Recruiting

  • Henry Ford Hospital ( Site 0035)

    Detroit, Michigan · Recruiting

  • Cancer and Hematology Centers of Western Michigan ( Site 0015)

    Grand Rapids, Michigan · Recruiting

  • Mayo Clinic in Rochester, Minnesota-Mayo Clinic Comprehensive Cancer Center ( Site 0078)

    Rochester, Minnesota · Recruiting

  • HealthPartners Cancer Research Center-HealthPartners Frauenshuh Cancer Center ( Site 0032)

    Saint Louis Park, Minnesota · Recruiting

  • HealthPartners Cancer Center at Regions Hospital ( Site 0052)

    Saint Paul, Minnesota · Recruiting

  • St. Vincent Frontier Cancer Center-Research ( Site 0037)

    Billings, Montana · Recruiting

  • Oncology Hematology West, PC dba Nebraska Cancer Specialists - Grand Island ( Site 0076)

    Grand Island, Nebraska · Completed

  • Oncology Hematology West P.C. dba Nebraska Cancer Specialists ( Site 0026)

    Omaha, Nebraska · Completed

  • Comprehensive Cancer Centers of Nevada ( Site 0082)

    Las Vegas, Nevada · Recruiting

  • John Theurer Cancer Center at Hackensack University Medical Center ( Site 0016)

    Hackensack, New Jersey · Recruiting

  • University of New Mexico Comprehensive Cancer Center ( Site 0022)

    Albuquerque, New Mexico · Recruiting

  • Icahn School of Medicine at Mount Sinai ( Site 0009)

    New York, New York · Recruiting

  • Great Lakes Cancer Care ( Site 0047)

    Williamsville, New York · Recruiting

Showing 40 of 303 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.